How an India-based biotechnology company is building the country’s deepest expertise in Bacillus spore science — and why the world’s formulators are paying attention
MUMBAI: There is a quiet problem at the heart of the global probiotics industry, and most consumers have never heard of it. A probiotic capsule may leave the factory with billions of live organisms inside it. By the time it reaches a pharmacy shelf in a humid coastal city, sits through a summer, and then travels through the acid of the human stomach, a large share of those organisms may no longer be alive to do anything at all.
Anneo Biotech has spent years working on the class of organisms that solves this problem elegantly — spore-forming probiotics.
From its GMP manufacturing facility in India, the company today produces some of the country’s most widely exported Bacillus probiotic biomass, supplying formulators, nutraceutical brands and pharmaceutical partners across Asia and beyond. Its flagship strain, Bacillus clausii ABBC2101, is manufactured at a standardised 100 billion CFU per gram in both powder and liquid presentations, and forms the backbone of finished products sold in several international markets.
The science: why a spore behaves differently
Most probiotic organisms in commercial use are vegetative bacteria — living, metabolically active cells that must be kept alive from fermenter to gut. They are sensitive to heat, moisture, oxygen and gastric acid. They often require cold-chain storage, protective encapsulation, and generous overages to compensate for what is lost along the way.
Spore-forming Bacillus species work on an entirely different principle.
Under defined conditions, these organisms form an endospore — a dormant, metabolically inert structure protected by a multi-layered proteinaceous coat and a dehydrated core stabilised by dipicolinic acid and calcium. In this state, the organism is not merely robust; it is functionally suspended. It withstands elevated temperatures, desiccation, mechanical stress, prolonged ambient storage and passage through gastric pH without meaningful loss of viability.
The spore then germinates in the more hospitable environment of the small intestine, returning to its vegetative state to perform its biological function — competitive exclusion of undesirable organisms, production of antimicrobial peptides and enzymes, and support of the resident microbial community — before transiting out of the body.
“A spore is nature’s own delivery system,” says Sarath, Business Development Officer and spokesperson for Anneo Biotech. “We did not invent it. What we have built is the manufacturing science, the strain library and the process control required to produce it consistently, at scale, to a standard that a global formulator can build a product around. That consistency is the entire business.”
Bacillus clausii — and the depth behind a single strain
Bacillus clausii occupies a particular position in probiotic science. It is a Gram-positive, alkaliphilic, spore-forming organism with a well-characterised tolerance profile, and it has a long clinical history in gastrointestinal formulations across Europe and Asia — most notably in oral suspension formats used in paediatric and adult gut-flora support.
What makes it commercially demanding is that it is unforgiving to manufacture. Sporulation efficiency, spore purity, heat-resistance characteristics and CFU stability are all sensitive to fermentation media design, aeration profile, harvest timing and downstream processing. Small deviations show up months later as failed stability studies.
Anneo Biotech’s process for ABBC2101 has been developed and refined specifically around these variables, and the strain is now a reference-grade input for several international finished-dose manufacturers.
Beyond clausii, the company’s Bacillus portfolio includes Bacillus coagulans — a lactic-acid-producing spore former increasingly favoured in functional foods and beverages precisely because it survives thermal processing — and Bacillus subtilis, valued for its enzyme secretion and biofilm-modulating behaviour. These sit within a broader 19-organism culture bank, including seven strains formally deposited with MTCC, alongside Lactobacillus rhamnosus, L. plantarum, L. reuteri, Bifidobacterium longum and Saccharomyces boulardii. The full strain and grade portfolio is published at www.anneobiotech.com.
“Anyone can buy a strain,” Sarath notes. “Very few organisations in this country can take a Bacillus strain from culture bank to a validated, reproducible, export-grade spore product with the documentation that a regulated market demands. That gap is where Anneo lives.”
Built for the customer, not the commodity market
Anneo Biotech has been deliberate about refusing the low-cost supplier position that Indian ingredient manufacturers are so often pushed into.
The company’s facility operates under ISO 9001:2015, FSSC 22000 v6.0, HACCP, Halal and Kosher certifications, and is progressing on a WHO-GMP approval pathway. Fermentation capacity currently stands at 2 KLPD, with an additional unit planned and further capacity being scaled at a second Indian site. A team of more than 70 people supports production, quality and technical service.
Crucially, the company’s model is not to ship a drum and disappear. Technical teams work directly with customers on strain selection, overage calculation, matrix compatibility, stability protocol design and regulatory documentation.
“Our customer is usually a formulator with a deadline and a specification they cannot compromise,” says Sarath. “They do not want marketing. They want a certificate of analysis that matches reality, a strain that behaves the same in batch 40 as it did in batch one, and a technical person who picks up the phone. We have built the company around those three things.”
The road ahead: from spore science to whole-body wellness
The company’s research and development agenda extends well past its current catalogue. Active workstreams include postbiotics — non-viable microbial fractions and metabolites that offer stability and safety advantages in sensitive populations — as well as selenium and organic trace-mineral yeasts, aquaculture-specific probiotic strains, and human milk oligosaccharides (HMOs), an area in which Indian manufacturing capability remains almost entirely absent.
On the prebiotic side, Anneo’s Fosnia range of fructo-oligosaccharides (L-55, L-65, L-95 and P-95 grades) and Anneo Inverta invert sugar are already supplied as functional ingredients, opening the door to synbiotic systems in which the company controls both the organism and its substrate.
“Spore science is our foundation, not our ceiling,” Sarath says. “The next decade of this industry belongs to companies that understand the whole system — the strain, the fibre that feeds it, the metabolites it produces, and the human being at the end of it. We intend to be one of them, and we intend to do it from India.”
For an industry that has often treated probiotics as a commodity powder, Anneo Biotech is making a different argument: that the science is the product, and that precision — in the strain, in the spore, in the specification — is what separates a supplier from a partner.
Formulators, brand owners and research partners can explore Anneo Biotech’s spore-forming probiotic range, technical documentation and sampling programme, or speak directly with the technical team, at www.anneobiotech.com.
About Anneo Biotech Anneo Biotech is an India-based biotechnology company specialising in the research, development and manufacture of probiotics, prebiotics, postbiotics and functional nutrition ingredients for human and animal health. Operating a GMP-certified manufacturing facility, the company maintains a 19-organism culture bank and supplies pharmaceutical, nutraceutical, food and feed customers across India and international markets. Anneo Biotech’s brand promise — Advancing Life. Together. — reflects its commitment to partnership-led innovation in microbial science.
